BibTex RIS Cite

Expression Profile of Transcription Factor ELK-1 and ELK-1 Target Genes on Lymphoma-Leukemia Cell Lines

Year 2018, Volume: 22 Issue: 2, 388 - 392, 15.08.2018

Abstract

Prognostic molecular markers identified in leukemia are becoming increasingly important especially in risk stratification and to determine therapy. In this study, we investigate the role of ELK-1 transcription factor and its potential target genes in four cell lines; Daudi, Jurkat, K-562 and HL-60. To evaluate ELK-1, MCPIP, MCL-1, BCL-10, CEBPB and SRF genes expression profiles we have performed a Real-time PCR analysis on Daudi, Jurkat, K-562 and HL-60 cell lines. ELK-1 over expression concomitant with SRF overexpression was detected only in Daudi cell line while only SRF overexpression was detected in jurkat cells. Expression of MCPIP, MCL-1, BCL-10 and CEBPB genes were decreased in all cell lines. Protein levels or phosphorylation status of ELK-1, BCL-10, CEBPB, MCL-1, MCPIP and SRF, moreover, changes that may occur when ELK-1 continuous overexpression is provided or completely silenced in these cell lines have not been evaluated. These questions are suggestions for future investigations.

References

  • [1] Walker A., Mrozek K., Kohlschmidt J., Rao K.W., Pettenati M.J., Sterling L.J., Marcucci G., Carroll A.J., Bloomfield C.D. 2013. New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461, Genes, Chromosomes and Cancer 52(4), 385-401.
  • [2] Shaffer L.G. 2013. Microarray - Based Cytogenetics in: S.L. Gersen, M.B. Keagle (Eds.) The Principles of Clinical Cytogenetics, Springer Science+Business Media, New York.
  • [3] Yasar D., Karadogan I., Alanoglu G., Akkaya B., Luleci G., Salim O., Timuragaoglu A., Toruner G.A., Berker-Karauzum S. 2010. Array comparative genomic hybridization analysis of adult acute leukemia patients, Cancer Genetics and Cytogenetics, 197(2), 122-129.
  • [4] Boros J., O'Donnell A., Donaldson I.J., Kasza A., Zeef L., Sharrocks A.D. 2009. Overlapping promoter targeting by Elk-1 and other divergent ETS-domain transcription factor family members, Nucleic Acids Research, 37(22), 7368-7380.
  • [5] Boros J., Donaldson I.J., O'Donnell A., Odrowaz Z.A., Zeef L., Lupien M., Meyer C.A., Liu X.S., Brown M., Sharrocks A.D. 2009. Elucidation of the ELK1 target gene network reveals a role in the coordinate regulation of core components of the gene regulation machinery, Genome Research, 19(11), 1963-1973.
  • [6] Cohen-Armon M. 2007. PARP-1 activation in the ERK signaling pathway, TRENDS in Pharmacological Sciences, 28(11), 556-560.
  • [7] Posern G., Treisman R. 2006. Actin' together: serum response factor, its cofactors and the link to signal transduction, Trends in Cell Biology, 16(11), 588-96.
  • [8] Schmeier S., MacPherson C.R., Essack M., Kaur M., Schaefer U., Suzuki H., Hayashizaki Y., Bajic V.B. 2009. Deciphering the transcriptional circuitry of microRNA genes expressed during human monocytic differentiation, BMC Genomics 10, 595.
  • [9] Wagner E.F., Nebreda A.R. 2009. Signal integration by JNK and p38 MAPK pathways in cancer development, Nature Reviews Cancer, 9(8), 537-49.
  • [10] McCormick F. 2011. Cancer therapy based on oncogene addiction, Journal of Surgical Oncology, 103(6), 464-7.
  • [11] Zhang R., Kim Y.M., Lu X., Wang X., Pang H., Li Y., Li S., Lee J.Y. 2011. Characterization of a novel t(2;5;11) in a patient with concurrent AML and CLL: a case report and literature review, Cancer Genetics 204(6), 328-33.
  • [12] Maicas M., Vazquez I., Vicente C., Garcia-Sanchez M.A., Marcotegui N., Urquiza L., Calasanz M.J., Odero M.D. 2013. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription, Oncogene, 32(16), 2069-78.
  • [13] Gade P., Roy S.K., Li H., Nallar S.C., Kalvakolanu D.V. 2008. Critical role for transcription factor C/EBP-beta in regulating the expression of death-associated protein kinase 1, Molecular and Cellular Biology, 28(8), 2528-2548.
  • [14] Uehata T., Akira S. 2013. mRNA degradation by the endoribonuclease Regnase-1/ZC3H12a/MCPIP-1, Biochimica et Biophysica Acta 1829(6-7), 708-713.
  • [15] Liang J., Saad Y., Lei T., Wang J., Qi D., Yang Q., Kolattukudy P.E., Fu M. 2010. MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB signaling, The Journal of Experimental Medicine, 207(13), 2959-2973.
  • [16] Cifuentes R.A., Cruz-Tapias P., Rojas-Villarraga A., Anaya J.M. 2010. ZC3H12A (MCPIP1): molecular characteristics and clinical implications, Clinica Chimica Acta 411(23-24), 1862-1868.
  • [17] Kasza A., Wyrzykowska P., Horwacik I., Tymoszuk P., Mizgalska D., Palmer K., Rokita H., Sharrocks A.D., Jura J. 2010. Transcription factors Elk-1 and SRF are engaged in IL1-dependent regulation of ZC3H12A expression, BMC Molecular Biology, 11, 14.
  • [18] Townsend K.J., Zhou P., Qian L., Bieszczad C.K., Lowrey C.H., Yen A., Craig R.W. 1999. Regulation of MCL1 through a serum response factor/Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation, The Journal of Biological Chemistry, 274(3), 1801-1813.
  • [19] Schimmer A.D., Hedley D.W., Penn L.Z., Minden M.D. 2001. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view, Blood 98(13), 3541-3553.
  • [20] Shih L.Y., Fu J.F., Shurtleff S.A., Morris S.W., Downing J.R. 2001. Lack of BCL10 mutations in multiple myeloma and plasma cell leukemia, Genes Chromosomes Cancer, 30(4), 402-406.
  • [21] VanGuilder H.D., Vrana K.E., Freeman W.M. 2008. Twenty-five years of quantitative PCR for gene expression analysis, Biotechniques, 44(5), 619-626.
  • [22] Sharrocks A.D. 2002. Complexities in ETS-domain transcription factor function and regulation: lessons from the TCF (ternary complex factor) subfamily. The Colworth Medal Lecture, Biochemical Society Transactions, 30(2), 1-9.
  • [23] Eilersi, P.H., de Menezes R. X. 2005. Quantile smoothing of array CGH data, Bioinformatics 21(7), 1146–1153.
Year 2018, Volume: 22 Issue: 2, 388 - 392, 15.08.2018

Abstract

References

  • [1] Walker A., Mrozek K., Kohlschmidt J., Rao K.W., Pettenati M.J., Sterling L.J., Marcucci G., Carroll A.J., Bloomfield C.D. 2013. New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461, Genes, Chromosomes and Cancer 52(4), 385-401.
  • [2] Shaffer L.G. 2013. Microarray - Based Cytogenetics in: S.L. Gersen, M.B. Keagle (Eds.) The Principles of Clinical Cytogenetics, Springer Science+Business Media, New York.
  • [3] Yasar D., Karadogan I., Alanoglu G., Akkaya B., Luleci G., Salim O., Timuragaoglu A., Toruner G.A., Berker-Karauzum S. 2010. Array comparative genomic hybridization analysis of adult acute leukemia patients, Cancer Genetics and Cytogenetics, 197(2), 122-129.
  • [4] Boros J., O'Donnell A., Donaldson I.J., Kasza A., Zeef L., Sharrocks A.D. 2009. Overlapping promoter targeting by Elk-1 and other divergent ETS-domain transcription factor family members, Nucleic Acids Research, 37(22), 7368-7380.
  • [5] Boros J., Donaldson I.J., O'Donnell A., Odrowaz Z.A., Zeef L., Lupien M., Meyer C.A., Liu X.S., Brown M., Sharrocks A.D. 2009. Elucidation of the ELK1 target gene network reveals a role in the coordinate regulation of core components of the gene regulation machinery, Genome Research, 19(11), 1963-1973.
  • [6] Cohen-Armon M. 2007. PARP-1 activation in the ERK signaling pathway, TRENDS in Pharmacological Sciences, 28(11), 556-560.
  • [7] Posern G., Treisman R. 2006. Actin' together: serum response factor, its cofactors and the link to signal transduction, Trends in Cell Biology, 16(11), 588-96.
  • [8] Schmeier S., MacPherson C.R., Essack M., Kaur M., Schaefer U., Suzuki H., Hayashizaki Y., Bajic V.B. 2009. Deciphering the transcriptional circuitry of microRNA genes expressed during human monocytic differentiation, BMC Genomics 10, 595.
  • [9] Wagner E.F., Nebreda A.R. 2009. Signal integration by JNK and p38 MAPK pathways in cancer development, Nature Reviews Cancer, 9(8), 537-49.
  • [10] McCormick F. 2011. Cancer therapy based on oncogene addiction, Journal of Surgical Oncology, 103(6), 464-7.
  • [11] Zhang R., Kim Y.M., Lu X., Wang X., Pang H., Li Y., Li S., Lee J.Y. 2011. Characterization of a novel t(2;5;11) in a patient with concurrent AML and CLL: a case report and literature review, Cancer Genetics 204(6), 328-33.
  • [12] Maicas M., Vazquez I., Vicente C., Garcia-Sanchez M.A., Marcotegui N., Urquiza L., Calasanz M.J., Odero M.D. 2013. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription, Oncogene, 32(16), 2069-78.
  • [13] Gade P., Roy S.K., Li H., Nallar S.C., Kalvakolanu D.V. 2008. Critical role for transcription factor C/EBP-beta in regulating the expression of death-associated protein kinase 1, Molecular and Cellular Biology, 28(8), 2528-2548.
  • [14] Uehata T., Akira S. 2013. mRNA degradation by the endoribonuclease Regnase-1/ZC3H12a/MCPIP-1, Biochimica et Biophysica Acta 1829(6-7), 708-713.
  • [15] Liang J., Saad Y., Lei T., Wang J., Qi D., Yang Q., Kolattukudy P.E., Fu M. 2010. MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB signaling, The Journal of Experimental Medicine, 207(13), 2959-2973.
  • [16] Cifuentes R.A., Cruz-Tapias P., Rojas-Villarraga A., Anaya J.M. 2010. ZC3H12A (MCPIP1): molecular characteristics and clinical implications, Clinica Chimica Acta 411(23-24), 1862-1868.
  • [17] Kasza A., Wyrzykowska P., Horwacik I., Tymoszuk P., Mizgalska D., Palmer K., Rokita H., Sharrocks A.D., Jura J. 2010. Transcription factors Elk-1 and SRF are engaged in IL1-dependent regulation of ZC3H12A expression, BMC Molecular Biology, 11, 14.
  • [18] Townsend K.J., Zhou P., Qian L., Bieszczad C.K., Lowrey C.H., Yen A., Craig R.W. 1999. Regulation of MCL1 through a serum response factor/Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation, The Journal of Biological Chemistry, 274(3), 1801-1813.
  • [19] Schimmer A.D., Hedley D.W., Penn L.Z., Minden M.D. 2001. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view, Blood 98(13), 3541-3553.
  • [20] Shih L.Y., Fu J.F., Shurtleff S.A., Morris S.W., Downing J.R. 2001. Lack of BCL10 mutations in multiple myeloma and plasma cell leukemia, Genes Chromosomes Cancer, 30(4), 402-406.
  • [21] VanGuilder H.D., Vrana K.E., Freeman W.M. 2008. Twenty-five years of quantitative PCR for gene expression analysis, Biotechniques, 44(5), 619-626.
  • [22] Sharrocks A.D. 2002. Complexities in ETS-domain transcription factor function and regulation: lessons from the TCF (ternary complex factor) subfamily. The Colworth Medal Lecture, Biochemical Society Transactions, 30(2), 1-9.
  • [23] Eilersi, P.H., de Menezes R. X. 2005. Quantile smoothing of array CGH data, Bioinformatics 21(7), 1146–1153.
There are 23 citations in total.

Details

Journal Section Articles
Authors

Duygu Yasar Sırın

Hande Akalan This is me

Publication Date August 15, 2018
Published in Issue Year 2018 Volume: 22 Issue: 2

Cite

APA Yasar Sırın, D., & Akalan, H. (2018). Expression Profile of Transcription Factor ELK-1 and ELK-1 Target Genes on Lymphoma-Leukemia Cell Lines. Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi, 22(2), 388-392. https://doi.org/10.19113/sdufbed.99971
AMA Yasar Sırın D, Akalan H. Expression Profile of Transcription Factor ELK-1 and ELK-1 Target Genes on Lymphoma-Leukemia Cell Lines. SDÜ Fen Bil Enst Der. August 2018;22(2):388-392. doi:10.19113/sdufbed.99971
Chicago Yasar Sırın, Duygu, and Hande Akalan. “Expression Profile of Transcription Factor ELK-1 and ELK-1 Target Genes on Lymphoma-Leukemia Cell Lines”. Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi 22, no. 2 (August 2018): 388-92. https://doi.org/10.19113/sdufbed.99971.
EndNote Yasar Sırın D, Akalan H (August 1, 2018) Expression Profile of Transcription Factor ELK-1 and ELK-1 Target Genes on Lymphoma-Leukemia Cell Lines. Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi 22 2 388–392.
IEEE D. Yasar Sırın and H. Akalan, “Expression Profile of Transcription Factor ELK-1 and ELK-1 Target Genes on Lymphoma-Leukemia Cell Lines”, SDÜ Fen Bil Enst Der, vol. 22, no. 2, pp. 388–392, 2018, doi: 10.19113/sdufbed.99971.
ISNAD Yasar Sırın, Duygu - Akalan, Hande. “Expression Profile of Transcription Factor ELK-1 and ELK-1 Target Genes on Lymphoma-Leukemia Cell Lines”. Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi 22/2 (August 2018), 388-392. https://doi.org/10.19113/sdufbed.99971.
JAMA Yasar Sırın D, Akalan H. Expression Profile of Transcription Factor ELK-1 and ELK-1 Target Genes on Lymphoma-Leukemia Cell Lines. SDÜ Fen Bil Enst Der. 2018;22:388–392.
MLA Yasar Sırın, Duygu and Hande Akalan. “Expression Profile of Transcription Factor ELK-1 and ELK-1 Target Genes on Lymphoma-Leukemia Cell Lines”. Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi, vol. 22, no. 2, 2018, pp. 388-92, doi:10.19113/sdufbed.99971.
Vancouver Yasar Sırın D, Akalan H. Expression Profile of Transcription Factor ELK-1 and ELK-1 Target Genes on Lymphoma-Leukemia Cell Lines. SDÜ Fen Bil Enst Der. 2018;22(2):388-92.

e-ISSN: 1308-6529